BETRF:OTC-BetterLife Pharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.095

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

400.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream that has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

+0.63 (+0.69%)

USD 34.60B
UCBJF UCB SA

N/A

USD 34.60B
ARGNF argenx SE

N/A

USD 31.72B
GNMSF Genmab A/S

-1.52 (-0.64%)

USD 15.44B
IVBIY IVBIY

N/A

USD 9.33B
ZLDPF Zealand Pharma A/S

N/A

USD 8.69B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.66B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 8.66B
WXIBF WuXi Biologics

N/A

USD 8.63B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 8.44B

ETFs Containing BETRF

CRAK VanEck Oil Refiners ETF 8.11 % 0.60 %

+0.14 (+0.89%)

USD 0.03B
GNR SPDR® S&P Global Natural.. 2.61 % 0.40 %

+0.26 (+0.89%)

USD 3.27B
XSOE WisdomTree Emerging Marke.. 1.63 % 0.32 %

+0.42 (+0.89%)

N/A
AVEM Avantis® Emerging Market.. 0.83 % 0.00 %

+0.58 (+0.89%)

USD 6.68B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 97.92% 87% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.92% 87% B+ 91% A-
Trailing 12 Months  
Capital Gain 75.93% 86% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.93% 86% B+ 88% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.42% N/A N/A 9% A-
Dividend Return -27.42% N/A N/A 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.86% N/A N/A 52% F
Risk Adjusted Return -56.11% N/A N/A 13% F
Market Capitalization 0.01B 54% F 41% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.